Artículos del autor

solaci

Chronic Ischemic cardiopathy

ESC 2020 | At Long Term, Diabetic Patients Benefit from Surgery

Data of this “real world” study have confirmed that diabetic patients with multivessel disease will benefit from...
solaci -
Chronic Ischemic cardiopathy

ESC 2020 | Post PCI Trimetazidine: No Adverse Events or Great Benefits

Trimetazidine in addition to optimal medical therapy in patients undergoing coronary PCI does not change events rate...
solaci -
Institutional News

SOLACI Webinar | Peripheral interventionism

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be...
solaci -
Coronary disease

4° ProEducar Educational Meeting – Complex Coronary Intervention

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be...
solaci -
Antiplatelet

ESC 2020 | Against the Grain, ASA Monotherapy Appears Superior after TAVR

After TAVR, patients with no anticoagulation indication are favored by monotherapy with aspirin (ASA) vs. dual antiaggregation...
solaci -
Other

ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality

Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in...
solaci -
Other

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and...
solaci -
Institutional News

The Most Read Articles of August in Interventional Cardiology

01- Myocardial Injury for COVID-19 Even in Young Patients with Mild Symptoms Most young COVID-19 patients not requiring...
solaci -